The Bio Report: A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery

Accumsan lacus vel facilisis volutpat. Tincidunt dui ut ornare lectus sit amet est placerat in. Neque egestas congue quisque egestas diam in arcu cursus euismod.

Presentations

This is some text inside of a div block.

November 22, 2023

Media Contacts

Related announcements

View All

Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform

Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting